Two newly developed CBD products significantly outperformed a standard isolate capsule in terms of absorption and overall bioavailability, according to a new clinical trial published in the Journal of Cannabis Research.
The study compared a bioavailability-enhanced CBD capsule and liquid formulation—both using surfactant/acid technology—to an unformulated CBD isolate capsule in 12 healthy male volunteers. Each subject received a single 40 mg dose of each product over three treatment periods, with two-week washouts in between. All doses were administered under low-fat fed conditions to limit the known effects of dietary fat on CBD absorption.
Researchers found that the enhanced capsule delivered the highest systemic CBD exposure, with a peak plasma concentration (C_max) of 14.1 ng/mL and a total exposure (AUC₀–₇₂) of 38.0 h·ng/mL. That compares to 6.2 ng/mL and 20.2 h·ng/mL for the enhanced liquid, and just 2.4 ng/mL and 11.7 h·ng/mL for the reference capsule.
On average, the enhanced capsule delivered a 5.7-fold higher peak concentration and a 3.3-fold higher AUC than the reference. The enhanced liquid achieved a 2.5-fold faster time to peak levels (median ~1 hour) and also outperformed the standard capsule in both measures. Inter-subject variability in drug exposure was also lower with the enhanced formulations.
No serious adverse events occurred, and the products were generally well tolerated. The only treatment-related side effect was a mild-to-moderate headache in four subjects, resolving without intervention. Cortisol levels remained within normal range throughout the study.
The findings suggest that these advanced formulations may offer more consistent and effective CBD delivery, even when taken with low-fat meals—potentially eliminating the need to co-administer CBD with fatty food to improve absorption. Researchers say further studies in women and long-term dosing scenarios are warranted.
More articles from The Marijuana Herald can be found below.
